Audrey Sternberg | Authors


Xevinapant Plus CRT in Locally Advanced HNSCC Shows Continued Benefit

September 11, 2022

Improvement in overall survival for patients with locally advanced head and neck squamous cell carcinoma was demonstrated with xevinapant plus standard chemoradiotherapy vs matched placebo at the 5-year mark.

Promising Safety With Sotorasib Plus Pembrolizumab for KRAS G12C+ NSCLC

August 07, 2022

Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.

Risk Factors Linked to Discontinuation of Adjuvant Abemaciclib in HR+/HER– Breast Cancer

June 06, 2022

Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.